, Volume 78, Issue 16, pp 1763–1767 | Cite as

Moxetumomab Pasudotox: First Global Approval

  • Sohita Dhillon
AdisInsight Report


Moxetumomab pasudotox-tdfk (LUMOXITI™), an anti CD22 recombinant immunotoxin, has been developed by MedImmune and its parent company AstraZeneca for the treatment of hairy cell leukaemia. The product, discovered at the National Cancer Institute, is an optimised version of immunotoxin CAT-3888. Moxetumomab pasudotox is composed of the Fv fragment of an anti-CD22 monoclonal antibody fused to a 38 kDa fragment of Pseudomonas exotoxin A, PE38. The Fv portion of moxetumomab pasudotox binds to CD22, a cell surface receptor expressed on a variety of malignant B-cells, thereby delivering the toxin moiety PE38 directly to tumour cells. Once internalised, PE38 catalyses the ADP ribosylation of the diphthamide residue in elongation factor-2 (EF-2), resulting in the rapid fall in levels of the anti-apoptotic protein myeloid cell leukaemia 1 (Mcl-1), leading to apoptotic cell death. This article summarizes the milestones in the development of moxetumomab pasudotox leading to this first approval for the treatment of adults with relapsed or refractory hairy cell leukaemia who received at least two prior systemic therapies, including treatment with a purine nucleoside analogue. Development of moxetumomab pasudotox for non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia and precursor cell lymphoblastic leukaemia/lymphoma was discontinued.


Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Sohita Dhillon is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.


  1. 1.
    Kreitman RJ, Arons E. Update on hairy cell leukemia. Clin Adv Hematol Oncol. 2018;16(3):205–15.PubMedGoogle Scholar
  2. 2.
    Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129(5):553–60.CrossRefGoogle Scholar
  3. 3.
    Getta BM, Park JH, Tallman MS. Hairy cell leukemia: past, present and future. Best Pract Res Clin Haematol. 2015;28(4):269–72.CrossRefGoogle Scholar
  4. 4.
    Kreitman RJ. Immunoconjugates and new molecular targets in hairy cell leukemia. Hematology. 2012;2012:660–6.PubMedGoogle Scholar
  5. 5.
    AstraZeneca. LUMOXITI™ (moxetumomab pasudotox-tdfk): US prescribing information. 2018. Accessed 4 Oct 2018.
  6. 6.
    FDA. FDA approves moxetumomab pasudotox-tdfk for hairy cell leukemia [media release]. 13 Sept 2018.
  7. 7.
    Alderson RF, Kreitman RJ, Chen T, et al. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res. 2009;15(3):832–9.CrossRefGoogle Scholar
  8. 8.
    Salvatore G, Beers R, Margulies I, et al. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res. 2002;8(4):995–1002.PubMedGoogle Scholar
  9. 9.
    Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011;17(20):6398–405.CrossRefGoogle Scholar
  10. 10.
    Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018;32(8):1768–77.CrossRefGoogle Scholar
  11. 11.
    Kuruvilla D, Chia YL, Santiago L, et al. Efficacy and safety of moxetumomab pasudotox (moxe) in adult patients (pts) with relapsed/refractory Hairy Cell Leukemia (HCL) in relation to drug exposure, baseline disease burden, and immunogenicity [abstract no. 7060]. J Clin Oncol. 2018;36(15 Suppl).CrossRefGoogle Scholar
  12. 12.
    Balic K, Standifer N, Santiago L, et al. Pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of Moxetumomab pasudotox (Moxe), an immunotoxin targeting CD22, in adult patients (Pts) with relapsed or refractory Hairy Cell Leukemia (HCL) [abstract no. 7061]. In: 54th annual meeting of the American Society of Clinical Oncology. 2018.CrossRefGoogle Scholar
  13. 13.
    Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012;30(15):1822–8.CrossRefGoogle Scholar
  14. 14.
    Kreitman RJ, Tallman MS, Robak T, et al. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood. 2018;131(21):2331–4.CrossRefGoogle Scholar
  15. 15.
    Kreitman R, Tallman MS, Robak T, et al. Negative minimal residual disease associated with extended response to moxetumomab pasudotox in patients with relapsed/refractory hairy cell leukemia: long-term follow-up of bone marrow immunohistochemistry analyses from a phase 1 study [abstract no. 2765]. Blood. 2017;130(Suppl 1).Google Scholar
  16. 16.
    Kreitman RJ, Arons E, Still K, et al. Moxetumomab pasudotox and minimal residual disease in hairy cell leukemia [abstract no. 7079]. J Clin Oncol. 2015;33(15 Suppl).Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations